Sign In
Buy NVCT
$18.44
+0.0900 (+0.490%)
At Close: Jul 13, 2026
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
10:40am, Tuesday, 14'th Jul 2026
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharma
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
10:55am, Wednesday, 08'th Jul 2026
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 01'st Jul 2026
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
10:30pm, Monday, 29'th Jun 2026
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 29'th Jun 2026
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
01:00pm, Friday, 26'th Jun 2026
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
08:34am, Monday, 22'nd Jun 2026
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group , targeting complement-mediated diseases and cancer to broad
Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of inn
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
10:56am, Monday, 25'th May 2026
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
07:30am, Thursday, 14'th May 2026
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
10:55am, Thursday, 07'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, th
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
07:30am, Tuesday, 05'th May 2026
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
08:00am, Tuesday, 31'st Mar 2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
07:30am, Wednesday, 11'th Feb 2026
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
